ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2006
Endocannabinoids and reactive nitrogen and oxygen species in neuropathologies.
Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Amelioration of Cytogenotoxic Damage in Drug Abusers Supplemented with Folic Acid.Biomedicines · 2024Article
- Endocannabinoids in neuroendopsychology: multiphasic control of mitochondrial function.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2012Review
- Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model.European journal of nuclear medicine and molecular imaging · 2012Article
- Ageing in worms: N-acylethanolamines take control.Protein & cell · 2011Article
- Endocannabinoids and the heart.Journal of cardiovascular pharmacology · 2009Review
- Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation.The Journal of biological chemistry · 2008Article
- Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke.Cardiovascular & hematological agents in medicinal chemistry · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Neuropathologies that affect our population include ischemic stroke and neurodegenerative diseases of immune origin, including multiple sclerosis. The endocannabinoid system in the brain, including agonists anandamide (arachidonyl ethanolamide) and 2-arachidonoylglycerol, and the CB1 and CB2 cannabinoid receptors, has been implicated in the pathophysiology of these disease states, and can be a target for therapeutic interventions. This review concentrates on cellular signal transduction pathways believed to be involved in the cellular damage.
Indexed as
Identifiers
18040807What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.